[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amyloidosis":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,51,86,111,135,166,215,237,292,314,335,361,387,409,436,457,480,530,553,591,611,627,647,671,696],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100599219","phase-1-a-phase-1b2-study-of-car-t-cell-therapy-targeting-cd19-and-bcma-in-participants-with-relapsed-or-refractory-al-amyloidosis-100599219",false,"NCT07081646","A Phase 1b\u002F2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","A Phase 1b\u002F2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.","ALACRITY","Inclusion Criteria:\n\n* Confirmed histopathological diagnosis of AL amyloidosis\n* One or more organs currently or historically impacted by AL amyloidosis according to consensus guidelines\n* Measurable hematologic disease: dFLC \\> 20 mg\u002FL or serum M-protein \\> 5g\u002FL\n* Relapsed or refractory disease with a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.\n* ECOG performance status of 0 to 2\n* Must be able and willing to adhere to the study visit schedule and other protocol requirements\n* Women of child-bearing potential (WCBP) must have a negative serum and\u002For urine pregnancy test result prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use highly effective methods of birth control throughout the study.\n\nExclusion Criteria:\n\n* Have any other form of amyloidosis other than AL amyloidosis\n* Mayo Stage IIIb AL amyloidosis\n* Oxygen saturation \\\u003C 95% on room air\n* Systolic blood pressure \\\u003C100mmHg\n* NYHA class III or IV\n* Extensive GI involvement with evidence of active GI bleeding\u002Frisk of bleeding as determined by Investigator\n* Prior therapies:\n\n  1. CAR T cell therapy directed at any target\n  2. Prior BCMA-targeting therapy\n  3. Prior treatment with any FDA approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.\n* Toxicity from previous anti-cancer or anti-PC-directed therapy did not resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.\n* Active plasma cell leukemia at the time of screening\n* Symptomatic multiple myeloma (defined as clonal bone marrow plasma cells ≥10% plus at least one myeloma-defining event per IMWG 2014)","ALL","18 Years",{"count":21,"type":22},91,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Open-label Phase 1b\u002F2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.",[29,30,31,32],"Relapsed AL Amyloidosis","Refractory AL Amyloidosis","Light Chain Amyloidosis","Amyloidosis",[34,35,36,37],"AZD0120","AL Amyloidosis","CAR-T","Cell Therapy","RECRUITING","2026-07-01",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":42},"2025-08-18",{"date":46,"type":22},"2031-02-14",{"name":48,"class":49},"Alexion Pharmaceuticals, Inc.","INDUSTRY",18,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420","NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","75 Years",{"count":60,"type":22},587,[62],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[32,65,66,67,68,69],"Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[32,71,72,73,74,75],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","2026-06-25",{"date":78,"type":42},"2026-06-29",{"date":80,"type":42},"2025-05-12",{"date":82,"type":22},"2032-12",{"name":84,"class":49},"Eidos Therapeutics, a BridgeBio company",103,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100495961","dietary-reporting-in-the-amyloidoses-100495961","NCT05738005","Dietary Reporting In The Amyloidoses","DRITA Pilot Trial: Dietary Reporting in the Amyloidoses","DRITA","Inclusion Criteria:\n\n* 18 years of age or older\n* Diagnosed with any type of amyloidosis\n* Speak, read and write in English\n* Willing to use the MyFitnessPal app on their own smartphone\n\nExclusion Criteria:\n\n* a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment\n* cognitive or perceptual disturbances",{"count":95,"type":22},40,[97],"NA","The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis.\n\nThe main question it aims to answer is:\n\nIs it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients\n\nParticipants will be asked to:\n\n* Download the MyFitnessPal application on their smartphone and view an online tutorial\n* After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal\u002Falternative supplement intake into the MyFitnessPal application on their smartphone.\n* complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application",[32],"2026-06-23",{"date":102,"type":42},"2026-06-26",{"date":104,"type":42},"2023-03-02",{"date":106,"type":22},"2028-11-21",{"name":108,"class":109},"Barbara Ann Karmanos Cancer Institute","OTHER",1,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":110},"100411373","prevalence-and-significance-of-attr-aortic-valve-amyloidosis-in-degenerative-aortic-stenosis-100411373","NCT04636684","Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis","RACAMYL","Inclusion Criteria:\n\n* Patient over 18 years old\n* Degenerative aortic stenosis\n* Aortic valve replacement surgery\n* Signature of the informed consent form\n\nExclusion Criteria:\n\n* Non-degenerative aortic stenosis: bicuspid, rheumatic disease, aortic regurgitation\n* Persons under a system of legal protection for adults (guardianship, curatorship, etc.)\n* Pregnant women","99 Years",{"count":120,"type":22},100,[97],"Cardiac amyloidosis is a restrictive cardiomyopathy with a potentially severe prognosis that can be life-threatening. It is linked in the vast majority of cases to a light chain deposition of immunoglobulin or transthyretin. Although myocardial involvement is predominant, other locations are possible: the atrioventricular conduction system, coronary arteries and valve leaflets. In systematic histological analyzes, deposits of amyloidosis infiltrating the aortic valve have been reported with a frequency of up to 74% for degenerative RA. The nature of these deposits has never been established because the immunostaining carried out all remained negative, probably due to decalcification prior to cutting. Currently, these deposits are considered to be local degenerative phenomena without clinical repercussions. However, the use of bone scintigraphy has shown a high prevalence, between 14 and 16%, of ATTR cardiac amyloidosis in patients with severe RA. The diagnosis of ATTR amyloidosis has been proven histologically in a few patients. Sequencing of the TTR gene has shown that they are mainly wild forms. In fact, the prevalence of transthyretin mutations in our local cohort is 20%.\n\nThe objective of this study is to determine by proteomic analysis based on mass spectrometry, the prevalence of ATTR aortic valve amyloidosis in patients undergoing surgical valve replacement for degenerative aortic stenosis.",[32],[125],"ATTR aortic valve amyloidosis","2026-05-28",{"date":128,"type":42},"2026-06-01",{"date":130,"type":42},"2020-12-01",{"date":132,"type":22},"2027-12-31",{"name":134,"class":109},"University Hospital, Toulouse",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":110},"100591011","phase-1-repeat-petct-imaging-in-people-with-caps-and-anakinra-induced-amyloidosis-using-an-amyloid-reactive-peptide-to-measure-changes-in-organ-specific-amyloid-load-100591011","NCT06974877","Repeat PET\u002FCT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load","A Phase 1 Study of Repeat PET\u002FCT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using Amyloid-Reactive Peptide 124I-AT-01 (124I-p5+14, Iodine-124I-Evuzamitide) to Measure Changes in Organ-Specific Amyloid Load","* INCLUSION CRITERIA:\n\nAn individual must meet all the following criteria to be eligible for this study:\n\n1. Aged 18 years and older.\n2. Currently enrolled on NIH protocol 17-I-0016 with a documented diagnosis of MWS or NOMID.\n3. Agree to allow data collected in this study to be shared with and stored on NIH protocol 17-I-0016 for that study s research analyses.\n4. Developed skin thickening at the site of anakinra injection.\n5. Participants who can become pregnant or who can impregnate their partner must agree to use 2 highly effective methods of contraception, at least 1 of which must be a barrier method, when engaging in sexual activities that can result in pregnancy, beginning 28 days prior to baseline until 90 days after the last PET\u002FCT scan. Acceptable methods of contraception include the following:\n\n   1. Barrier methods:\n\n      * External or internal condom with spermicide.\n      * Diaphragm or cervical cap with a spermicide.\n   2. Non-barrier methods:\n\n      * Hormonal contraception.\n      * Intrauterine device.\n      * Hysterectomy, oophorectomy, or tubal ligation in women\n      * Vasectomy in men\n   3. Other.\n\nEXCLUSION CRITERIA:\n\n1. Known hypersensitivity to 124I-AT-01, AT-01, or any of their excipients.\n2. Known hypersensitivity to KI.\n3. Pregnant or breastfeeding.\n4. Currently receiving dialysis.\n5. Currently taking heparin or heparin derivatives (eg, low molecular weight heparins) or other blood thinners for anticoagulation.\n6. Any condition that, in the opinion of the study team, contraindicates participation in this study.","120 Years",{"count":144,"type":22},30,[25],"Background:\n\nAnakinra is a drug used to treat people with certain diseases that affect their immune systems. Sometimes anakinra can cause proteins under the skin to clump together. These clumps are called amyloidosis; they can spread to other organs. The only way to diagnose amyloidosis is to remove a piece of tissue (biopsy). Researchers want to find a way to locate amyloidosis in internal organs using positron emission tomography (PET)\u002Fcomputed tomography (CT).\n\nObjective:\n\nTo test a new tracer used during PET\u002FCT scans in people with amyloidosis. A tracer is a radioactive dye injected into the body.\n\nEligibility:\n\nAdults aged 18 years or older with amyloidosis from anakinra injections. They must be enrolled in NIH protocol 17-I-0016.\n\nDesign:\n\nParticipants will come to the clinic once every 6 months for 2 years. Each visit will be 1 day.\n\nThey will have a PET\u002FCT scan with the new tracer at each visit: The tracer will be given through a tube attached to a needle inserted into a vein.\n\nThe PET\u002FCT scanner is a machine shaped like a doughnut. Participants will lie still on a padded table. The table will move in and out of the machine. The scan takes about 1 hour.\n\nRadiation from the tracer will remain in the body for 24 hours after each scan. Participants will need to follow rules to avoid exposing pets and other people.\n\nParticipants will collect a 24-hour urine sample before each visit. They will also have blood tests and a physical exam at each visit.\n\nParticipants will receive a follow-up phone call about 1 week after each visit.",[148,32],"Cryopyrin-Associated Periodic Syndromes",[150,151,152,153,154,155],"Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease","Interleukin 1 Receptor Antagonist Protein","Anakinra","AMYLOIDOSIS","AIL1RAP","2026-05-16",{"date":158,"type":42},"2026-05-19",{"date":160,"type":42},"2025-09-10",{"date":162,"type":22},"2032-01-31",{"name":164,"class":165},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":110},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":174,"type":22},27,[26],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[32,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205],"Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":208,"type":42},"2026-05-18",{"date":210,"type":42},"2025-12-18",{"date":212,"type":22},"2026-12-18",{"name":214,"class":109},"Mayo Clinic",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":236},"100450463","phase-1-phase-12a-study-of-belantamab-mafodotin-in-relapsed-or-refractory-al-amyloidosis-100450463","NCT05145816","Phase 1\u002F2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis","A Dose-Finding and Proof-of-Concept Phase 1\u002F2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis","Inclusion Criteria:\n\n1. Participants medically diagnosed with relapsed or refractory Amyloid Light Chain Amyloidosis (AL amyloidosis) with one or more line of treatment as below:\n\n   1. Must have received a proteosome inhibitor, alkylator and anti-cluster of differentiation 38 (CD38) antibody (e.g., daratumumab - for patients who were eligible to receive in newly diagnosed AL Amyloidosis) and autologous stem cell transplant (for transplant eligible candidates).\n\n      OR\n   2. Failed treatment and\u002For intolerant\u002Fineligible for above agents\n\n   NOTE: Patients who fail to achieve Partial Hematological Response or better after 2 cycles of induction therapy for newly diagnosed AL Amyloidosis are also eligible.\n2. Participant must be over 18 years of age inclusive, at the time of signing the informed consent.\n3. Participant and Disease Characteristics: Patient must have primary systemic AL amyloidosis, histologically confirmed at the initial diagnosis before initiation of 1st-line treatment by positive Congo red stain with green birefringence on polarized light microscopy, Or characteristic appearance by electron microscopy AND confirmatory AL amyloid typing (mass spectrometry-based proteomic analysis or immunofluorescence).\n4. Patient must have measurable disease within 28 days prior to registration; serum quantitative immunoglobulins (immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM), serum free kappa and lambda, and serum protein electrophoresis (SPEP) with M-protein quantification must be obtained within 14 days prior to registration.\n5. Measurable disease of amyloid light chain amyloidosis as defined by at least One of the following:\n\n   a. Serum M-protein ≥0.5 g\u002FdL by protein electrophoresis (routine serum protein electrophoresis and immunofixation).\n\n   b. Serum free light chain ≥50 mg\u002FL with an abnormal kappa: lambda ratio or the difference between the involved and uninvolved free light chains (dFLC) ≥50 mg\u002FL.\n6. One or more organs impacted by AL Amyloidosis according to consensus guidelines below per National Comprehensive Cancer Network (NCCN)Guidelines Version 1.2016:\n\n   a. Cardiac Involvement i. Mean left ventricular wall thickness on echocardiogram greater than or equal to 12 mm in the absence of hypertension or valvular heart disease, OR N-terminal fragment brain natriuretic protein (NT-pro) brain natriuretic peptide (BNP) greater than 332 ng\u002FmL provided that patient does not have impaired renal function (as defined by calculated creatinine clearance less than 25 mL\u002Fmin) within 14 days prior to registration, OR prior cardiac biopsy (at time of diagnosis) showing amyloid deposition with past documented or presently noted clinical symptoms and signs supportive of a diagnosis of heart failure in the absence of an alternative explanation for heart failure.\n\n   b. Non-Cardiac Organ Involvement\n\n   i. Kidney: albuminuria greater than or equal to 500 mg per day on a 24-hour urine specimen within 35 days prior to registration, OR prior kidney biopsy (at the time of diagnosis) showing amyloid deposition.\n\n   ii. Liver: hepatomegaly (total liver span \\> 15 cm) as demonstrated by computed tomography (CT) or magnetic resonance imaging (MRI) within 35 days prior to registration OR alkaline phosphatase (ALP) greater than 1.5 times the institutional upper limit of normal within 14 days prior to registration, OR prior liver biopsy (at the time of diagnosis) showing amyloid deposition.\n\n   iii. Gastrointestinal tract: direct biopsy verification with symptoms.\n\n   iv. Lung: biopsy verifications with symptoms and interstitial radiographic pattern.\n\n   v. Soft tissue: tongue enlargement, clinical, arthropathy, claudication, presumed vascular amyloid, skin involvement, carpal tunnel syndrome, myopathy by biopsy or pseudohypertrophy.\n7. Patients must have completed other systemic therapy or investigational drug ≥ 28 days or five half-lives prior to registration, surgery (other than biopsies) ≥ 28 days prior to registration, and any autologous stem cell transplant (ASCT) ≥ 100 days prior to registration.\n8. Patients must have a complete medical history and physical exam within 14 days prior to registration.\n9. New York Heart Association (NYHA) Class 1 - 3a which has been clinically stable for 56 days before registration\n10. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2\n11. Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) \\> 35% within 28 days prior to registration.\n12. Adequate organ system functions within 14 days of registration as defined by the laboratory assessments below:\n\n    a) Hematologic i) Absolute neutrophil count (ANC): ≥1.0 × 10(9)\u002F L \\* ii) Hemoglobin: ≥8.0 g\u002FdL \\* iii) Platelets: ≥50 × 10(9)\u002FL \\*\n\n    b) Hepatic i) Total bilirubin: ≤1.5 × upper limit of normal (ULN); (Isolated bilirubin ≥1.5 × ULN is acceptable if bilirubin is fractionated, and direct bilirubin is \\\u003C35%) ii) Alanine aminotransferase (ALT): ≤2.5 × ULN\n\n    c) Renal i) Estimated glomerular rate (eGFRª): ≥30 mL\u002Fmin\u002F1.73 m2 Note: Laboratory results obtained during Screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the participant and the subsequent within range screening result may be used to confirm eligibility.\n\n    \\* Without growth factor or cell transfusion support for the past 14 days prior to testing, excluding erythropoietin.\n\n    ª As calculated by Modified Diet in Renal Disease (MDRD) formula (Appendix 4 in Protocol)\n13. Females of childbearing potential: These participants must have a negative baseline pregnancy test using serum or urine within 14 days prior to starting therapy and a confirmatory negative serum pregnancy test with a sensitivity of at least 50 mIU\u002FmL within 72 hours prior to registration; females of childbearing potential must also agree:\n\n(1) to have a pregnancy test prior to the start of each treatment cycle and (2) to either commit to continued abstinence from heterosexual intercourse or to use effective contraception while receiving study drug and for at least 4 months after receiving the last dose of study drug; females are considered to be of childbearing potential if they have had menses at any time in the preceding 24 consecutive months; in addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures.\n\n1. Is a woman of child bearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency (as described in Appendix 9), during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n2. A WOCBP must have a negative serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.\n3. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.\n4. Non-childbearing potential is defined as follows (by other than medical reasons):\n\ni. ≥45 years of age and has not had menses for \\>1 year.\n\nii. Patients who have been amenorrhoeic for \\\u003C2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation.\n\niii. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n\n14\\. Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n\n1. Refrain from donating sperm\n\n   Plus, either:\n2. be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent\n\n   Or\n3. agree to use a barrier method of birth control (e.g., male condom), even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \\\u003C1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females).\n\n   15\\. Patients with Human Immunodeficiency Virus (HIV) infection are eligible if:\n\na. patients without a history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections\n\nb. patients with a history of AIDS-defining opportunistic infection may be eligible if they have not had an opportunistic infection within past 12 months.\n\nc. Patients on active anti-retroviral therapy are eligible as long as anti-retroviral therapy is established for at least four weeks and have HIV viral load less than 400 copies\u002Fml prior to enrollment.\n\n16\\. Patients with chronic Hepatitis B Virus (HBV) infection or chronic Hepatitis C Virus (HCV) infection or virologically suppressed on HCV treatment are eligible if:\n\n1. Hepatitis B surface antigen (HBsAg)-negative, anti-Hemoglobin C (HBc)-positive patients are at lower risk of HBV reactivation compared with HBsAg-positive patients, risk of HBV reactivation should be considered in all patients and if patients can be on anti-HBV prophylaxis prior to initiation of anti-cancer therapy.\n2. Patients with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to initiation of cancer therapy.\n3. Patients actively on treatment for HCV should have HCV below the limit of quantification before initiation of anti-cancer therapy.\n4. Patients who are HCV antibody (Ab) positive but HCV Ribonucleic Acid (RNA) negative due to prior treatment or natural resolution of infection are eligible.\n\nExclusion Criteria:\n\n1. Patients previously treated for active symptomatic multiple myeloma.\n2. Any corneal disease except for mild epithelial punctate keratopathy.\n3. Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.\n4. Patients eligible for autologous stem cell transplantation (ASCT).\n5. Evidence of significant cardiovascular condition as specified below:\n\n   1. N-terminal-prohormone of brain natriuretic peptide (NT-proBNP) ≥ 8500ng\u002FL within 14 days of registration.\n   2. New York Heart Association (NYHA) classification IIIB (3b) through IV (4) heart failure\n   3. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram (ECG) changes) or uncorrected valvular disease and not primarily due to AL amyloid cardiomyopathy\n   4. Unstable heart failure defined as emergency hospitalization for worsening, or decompensated heart failure, or syncopal episode within 1 month of screening\n   5. Subjects with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker\u002Fimplantable cardioverter-defibrillator (ICD) is indicated but not placed (Subjects who do have a pacemaker\u002FICD are allowed on study)\n   6. Interval from the Q wave on the ECG to point T using Fredericia's formula (QTcF) \\> 500 msec. Subjects who have a pacemaker may be included regardless of calculated QTc interval\n   7. Symptomatic, clinically significant autonomic neuropathy which the Investigator feels will preclude administration of study treatment\n   8. Acute coronary syndrome, or any form of coronary revascularization procedure including coronary artery bypass grafting (CABG), within 6 months of screening\n   9. Prior solid organ transplant, or anticipated to undergo solid organ transplantation, or requiring left ventricular assist device (LVAD) implantation, during the course of the study\n   10. Stroke within 6 months of screening, or transient ischemic attack (TIA) within 3 months of screening\n   11. Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n   12. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of Screening\n   13. Uncontrolled hypertension\n6. Prior history of malignancy with the exception of the following: adequately treated basal cell or squamous cell skin cancer, curatively treated non-melanoma skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least two years.\n7. Presence of any comorbid or uncontrolled medical condition (e.g. uncontrolled hypertension) - defined as defined as an average SBP ≥ 160mm Hg or diastolic ≥ 100mm Hg despite optimal treatment) at screening, which in the opinion of the investigator would increase the potential risk to the subject.\n8. Unwillingness or inability to follow the procedures outlined in the protocol.\n9. Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks or five half-lives, whichever is shorter, before Cycle 1 Day 1.\n10. Participant must not use contact lenses while participating in this study.\n11. Participant must not have had major surgery ≤ 4 weeks prior to initiating study treatment.\n12. Participant must not have any evidence of active mucosal or internal bleeding.\n13. Participant must not have any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.\n14. Participants must not be pregnant or lactating.\n15. Participant must not be simultaneously enrolled in any interventional clinical trial.\n16. Participant must not have an active infection requiring treatment.\n17. Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria.",{"count":223,"type":22},37,[25,26],"The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug.\n\nThe study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1",[35,32],"2026-05-01",{"date":229,"type":42},"2026-05-07",{"date":231,"type":42},"2024-02-15",{"date":233,"type":22},"2027-09-01",{"name":235,"class":109},"University of Texas Southwestern Medical Center",3,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":268,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","85 Years",{"count":246,"type":22},60,[62],"This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[250,251,252,253,254,255,256,257,258,259,260,261,32,69,262,263,264,265,266,267],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[75,32,269,270,271,72,272,73,273,274,275,276,277,278,279,280,281],"Polyneuropathy","NTLA-2001","ATTR","ATTRv-PN","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","2026-04-13",{"date":284,"type":42},"2026-04-16",{"date":286,"type":42},"2024-11-22",{"date":288,"type":22},"2028-08",{"name":290,"class":49},"Intellia Therapeutics",14,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":118,"enrollmentInfo":300,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":110},"100535434","national-referral-center-study-of-transthyretin-amyloid-cardiomyopathyattr-patients-on-tafamidis-100535434","NCT06251778","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis: Real World Prospective Study","NOTE-ATTR","Inclusion Criteria:\n\n* Diagnosis of ATTRwt amyloidosis.\n* 18 years or older;\n* evidence of cardiac involvement at echocardiography or cardiac MRI.\n* No known prior history of atrial fibrillation or major bradyarrhythmia (second degree atrioventricular block, third-degree atrioventricular block, high-grade atrioventricular block or alternating right and left branch block)\n* female patients who are postmenopausal for at least 1 year before the screening visit\n* patients on therapy or candidates for therapy with tafamidis 61 mg\n* voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\n* Non-ATTR amyloidosis;\n* NYHA class III and IV;\n* Pregnant or nursing women;\n* Previous pacemaker implantation;\n* any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with a fully comprehension of the written consent form",{"count":301,"type":22},200,"OBSERVATIONAL","All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in ATTRwt patients. Moreover, particular attention is usually paid for those who present atrio-ventricular and\u002For intraventricular block at the baseline electrocardiogram. Data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the Holter ECG monitoring requested by the physician at the end of every planned clinical evaluation.",[32,305,306],"Amyloidosis Cardiac","ATTR Amyloidosis Wild Type",{"date":284,"type":42},{"date":309,"type":42},"2024-01-26",{"date":311,"type":22},"2027-01-26",{"name":313,"class":109},"Paolo Milani",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":110},"100497534","phase-2-characterizing-iodine-124-evuzumitide-at-01-in-systemic-amyloidosis-100497534","NCT05758493","Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis","Inclusion Criteria:\n\n1. Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance\n2. Patient willing to consent for the study and undergo the study procedures.\n\nExclusion Criteria:\n\n1. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol\n2. Has a known allergy to potassium iodide treatment or to gadolinium.\n3. Patients on dialysis or those with eGFR \\\u003C30 cc\u002Fmin\u002F1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI.\n4. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration","40 Years","90 Years",{"count":323,"type":22},150,[26],"This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET\u002FMRI). In a subgroup of patients who are unable to undergo PET\u002FMR, computed tomography will be used instead of MRI (i.e. PET\u002FCT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.",[32,66],"2026-04-06",{"date":282,"type":42},{"date":330,"type":42},"2023-01-10",{"date":332,"type":22},"2028-03-10",{"name":334,"class":109},"Oregon Health and Science University",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":351,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":110},"100630997","impact-of-a-cardiac-rehabilitation-program-on-patients-with-cardiac-amyloidosis-100630997","NCT07494942","Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis","RECARDA","Inclusion Criteria:\n\n* Age 18 or older\n* Cardiac ATTR amyloidosis diagnosed according to guidelines: Perugini grade II or III uptake on bone scintigraphy, without monoclonal gammopathy.\n* Ability to undergo a stress test\n* Available to complete the 5-week rehabilitation program within 30 days of the stress test\n\nExclusion Criteria:\n\n* Uncontrolled ventricular arrhythmias\n* NYHA Class IV heart failure\n* Inability to give informed consent to participate in the study\n* Inability to monitor the patient during the study period\n* Subject not enrolled in a social security program or not eligible for such a program\n* Pregnant or breastfeeding women, patients unable to give consent, protected adults, vulnerable persons\n* Subjects deprived of liberty by judicial or administrative decision",{"count":95,"type":22},[97],"The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability to exercise and their quality of life. The main questions it aims to answer are:\n\nDoes cardiac rehabilitation raise peak oxygen uptake (VO₂ peak), which shows how well the heart and lungs work during exercise? Is cardiac rehabilitation safe and practical for people with cardiac amyloidosis? How does cardiac rehabilitation affect other exercise measures, heart function, symptoms linked to autonomic dysfunction, and quality of life?\n\nThis study has no comparison group. Researchers will measure each participant's results before and after the rehabilitation program.\n\nParticipants will:\n\nComplete a cardiac rehabilitation program for 5 weeks. Have tests before the program starts and again about 3 months later. These tests include:\n\nA cardiopulmonary exercise test A heart function test using electrical impedance A questionnaire about quality of life A blood sample A blood pressure test to check for orthostatic hypotension\n\nThe study will include adults aged 18 or older with transthyretin cardiac amyloidosis who are able to perform an exercise test.",[32],[347,348,349,350],"Cardiac Amyloidosis","Cardiac Rehabilitation","Heart Failure","ATTR Amyloidosis","NOT_YET_RECRUITING","2026-03-26",{"date":354,"type":42},"2026-04-01",{"date":356,"type":22},"2026-04-30",{"date":358,"type":22},"2029-01-30",{"name":360,"class":109},"University Hospital, Montpellier",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":351,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100610214","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-belantamab-mafodotin-in-combination-with-cyclophosphamide-bortezomib-and-dexamethasone-in-adult-participants-with-newly-diagnosed-amyloid-light-chain-al-amyloidosis-100610214","NCT07224672","A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis","A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)","ALANIS","Inclusion criteria:\n\n* Participant is at least 18 years of age or the legal age of consent\n* Has histologically confirmed newly diagnosed primary AL amyloidosis according to the following criteria:\n\n  * Presence of an amyloid-related systemic syndrome as per consensus guidelines.\n  * Positive amyloid staining by Congo red stain with green birefringence on polarized light microscopy in any tissue AND at least 1 of the following tests to confirm amyloid type as AL Characteristic appearance by electron microscopy or confirmatory immunohistochemistry or AL amyloidosis typing by mass spectrometric proteomic analysis of the amyloid deposits or amyloid-typing by immunofluorescence oEvidence of a monoclonal plasma cell proliferative disorder\n* Measurable clonal disease as defined by at least 1 of the following:\n\n  * Serum monoclonal protein \\>=0.5 grams per deciliter (g\u002FdL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation performed at central laboratory),\n  * Involved serum FLC \\>=5.0 milligram per deciliter (mg\u002FdL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved light chain, FLC concentrations (dFLC) \\>=5 mg\u002FdL.\n* Not considered candidate for high-dose chemotherapy with autologous stem cell transplantation (ASCT) as part of first line of therapy\n* Is willing to use adequate contraception.\n* Is capable of giving signed informed consent\n* Has an Eastern Cooperative Oncology Group performance status of 0, 1 or 2\n* Has adequate hematologic, hepatic and renal function\n\nExclusion criteria:\n\n* Has a previous or current diagnosis of plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome or symptomatic multiple myeloma (MM), as per International Myeloma Working Group criteria for MM including the presence of lytic bone disease , plasmacytomas, or clonal BM plasma cells \\>=60%.\n* Has Immunoglobulin M (IgM)-related AL amyloidosis.\n* Has any form of non-AL amyloidosis, including wild type or mutated (Transthyretin amyloidosis \\[ATTR\\]) amyloidosis.\n* Has evidence of significant cardiovascular (CV) conditions as specified below:\n\n  * New York Heart Association (NYHA) classification IIIb or IV heart failure.\n  * Heart failure that in the opinion of the investigator is caused by ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram \\[ECG\\] changes) or uncorrected valvular disease and not primarily due to AL amyloidosis cardiomyopathy.\n  * In-participant admission to a hospital for unstable angina or myocardial infarction within the last 3 months prior to screening or percutaneous cardiac intervention with recent stent within last 3 months prior to screening or coronary artery bypass grafting within the last 3 months prior to screening\n  * Participants with current evidence of clinically significant untreated arrhythmia(s), including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.\n  * Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker\u002Fimplantable cardioverter-defibrillator is indicated but not placed (participants who do have a pacemaker\u002Fimplantable cardioverter-defibrillator are allowed on the study).\n  * Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) \\>450 millisecond (msec) or \\>480 msec for participants with bundle branch block. Participants who have a pacemaker may be included regardless of calculated QTc interval.\n  * Supine systolic blood pressure \\\u003C90 millimeters of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of \\>20 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion.\n  * Uncontrolled hypertension.\n* Has Mayo stage 3B disease\n* Has a current corneal epithelial disease except for mild punctate keratopathy.\n* Has previous or concurrent malignancies other than AL amyloidosis, except for any other malignancy that has been considered medically stable for at least 2 yearsThe participant must not be receiving active therapy, other than hormonal therapy for this disease.\n* Has major surgery within 2 weeks prior to the first dose of study interventions or has not recovered fully from surgery.\n* Has any history of prior allogenic or autologous BM transplant or other solid organ transplant.\n* Has known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, cyclophosphamide, bortezomib, boron or mannitol\n* Has active infection or active bleeding.\n* Has intolerance or contraindications to antiviral prophylaxis.\n* Has known Human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:\n\n  * Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \\\u003C400 copies\u002Fmilliliter (mL) Cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts \\>=350 cells\u002Fmicroliter.\n  * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.\n* Has prior therapy for AL amyloidosis or MM, with the exception of 160 milligram (mg) dexamethasone (or equivalent corticosteroid) maximum exposure prior to enrollment.\n* Has received any live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin\n* Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research within 28 days before enrollment.\n* Has an alanine aminotransferase (ALT) value \\>2.5\\*upper limit of normal (ULN) or \\>3\\*ULN if hepatic involvement of AL amyloidosis\n* Has a total bilirubin value \\>1.5\\*ULN\n* Has cirrhosis or current unstable liver or biliary disease per investigator assessment Has documented presence of Hepatitis B surface antigen (HBsAg) and\u002For Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention, unless HBV DNA is undetectable at screening and participant receives antiviral prophylaxis or treatment.\n* Has a positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the following criteria are met:\n\n  * RNA test negative.\n  * Successful antiviral treatment (usually 8 weeks duration), followed by a negative Hepatitis C virus RNA test after a washout period of at least 4 weeks.\n* Chronic hepatitis B infection, with the presence of HBsAg and\u002For detectable hepatitis B virus deoxyribonucleic acid (HBV DNA), and hepatitis D co-infection, with hepatitis D antibody and\u002For RNA, within 3 months",{"count":246,"type":22},[26],"The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .",[32],[374,375,376,377],"Amyloid light chain amyloidosis","Bortezomib","Cyclophosphamide","Dexamethasone","2026-03-13",{"date":380,"type":42},"2026-03-17",{"date":382,"type":22},"2026-03-20",{"date":384,"type":22},"2032-12-13",{"name":386,"class":49},"GlaxoSmithKline",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":394,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":408},"100606183","beamycon-biobank--data-registry-uz-leuven-100606183","NCT07172243","BE.Amycon Biobank & Data Registry UZ Leuven","BE.Amycon Biobank & Data Registry UZ Leuven: Human Body Material (HBM) Collection and Data Collection of Patients With Amyloidosis","Inclusion Criteria:\n\n* Provide consent and sign informed consent form\n* Age 18 years or older\n* Diagnosis of amyloidosis (suspected or confirmed, any subtypes)\n* For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis)\n\nExclusion Criteria:\n\n* Not willing to sign informed consent\n* Not able to sign informed consent",true,{"count":396,"type":22},505,"The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank \"BE.Amycon biobank\" for future research and to collect clinical data of patients with amyloidosis in a database \"BE.Amycon data registry\".",[32,35,305],"2026-02-23",{"date":401,"type":42},"2026-02-27",{"date":403,"type":42},"2025-09-24",{"date":405,"type":22},"2030-01",{"name":407,"class":109},"Universitaire Ziekenhuizen KU Leuven",2,{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":415,"phases":4,"briefSummary":416,"conditions":417,"keywords":423,"overallStatus":430,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":434,"locationsCount":4},"100295215","expanded-access-to-venetoclax-100295215","NCT03123029","Expanded Access to Venetoclax","Exclusion Criteria:\n\n* There are other suitable treatment options.\n* The participant qualifies for ongoing clinical trials.","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[418,197,419,420,421,32,422],"Chronic Lymphocytic Leukemia (CLL)","Acute Myeloid Leukemia (AML)","Non-Hodgkin's Lymphoma","Acute Lymphoblastic Leukemia (ALL)","Plasma Cell Leukemia",[424,425,426,427,428,429],"Expanded Access","Pre-approval Access","Compassionate Use","Special Access Program","Named Patient Basis","Special Access Scheme","AVAILABLE","2026-01-29",{"date":433,"type":42},"2026-01-30",{"name":435,"class":49},"AbbVie",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":110},"100622821","phase-3-a-study-to-evaluate-the-safety-and-efficacy-of-sctc21c-in-combination-with-bortezomib-cyclophosphamide-and-dexamethasone-in-patients-with-newly-diagnosed-systemic-light-chain-amyloidosis-ndslca-100622821","NCT07388602","A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone Versus Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in congo red stained tissue specimens or characteristic electron microscopy appearance;\n* Measurable disease of amyloid light-chain (AL) amyloidosis;\n* One or more organs impacted by AL amyloidosis according to consensus guidelines\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2\n\nExclusion Criteria:\n\n* Prior therapy for AL amyloidosis;\n* Other amyloidosis;\n* Uncontrolled infection.\n* Subjects with conditions that may affect safety or efficacy assessments include, but are not limited to, cardiovascular, respiratory, endocrine\u002Fmetabolic, immune system, hepatic, gastrointestinal (such as gastrointestinal bleeding, perforation, ulcers, etc.), and malignant neoplasms, and are deemed clinically significant by the investigator.\n* Subjects who have undergone major surgery or experienced significant trauma within 4 weeks prior to the first use of the investigational drug, or who require elective surgery during the trial period.\n* Received a live or attenuated vaccine within 30 days prior to the first dose; Female subjects who are currently breastfeeding.\n* Subjects with mental disorders or poor compliance, or other circumstances deemed unsuitable for participation in this study by other investigators.",{"count":444,"type":22},90,[62],"The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.",[32],"2026-01-28",{"date":450,"type":42},"2026-02-05",{"date":452,"type":42},"2026-01-08",{"date":454,"type":22},"2028-12",{"name":456,"class":49},"Sinocelltech Ltd.",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":110},"100159358","hiba-institutional-registry-of-amyloidosis-100159358","NCT01347047","HIBA-Institutional Registry of Amyloidosis","Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)","RIA-HIBA","Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and\u002For there is amyloidosis in a biopsy specimen and\u002For requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis\n\n\\*\\*Inclusion Criteria: 1 AND (2 or 3)\n\n1. Patients over 18 years:\n2. Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)\n3. Clinically compatible case of Amyloidosis :\n\n   * Exclusion Criteria:\n\nRefusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.",{"count":466,"type":22},500,"1. Creating a population-based registry system Amyloidosis prospective epidemiological survey\n\n   * risk factors\n   * diagnosis\n   * prognosis\n   * treatment\n   * monitoring\n   * survival\n2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires.\n3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.",[32],[32,470,471],"Known or Suspected","rare diseases","2026-01-20",{"date":474,"type":42},"2026-01-22",{"date":476,"type":42},"2011-04",{"date":405,"type":22},{"name":479,"class":109},"Hospital Italiano de Buenos Aires",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":487,"targetDuration":489,"studyType":302,"phases":4,"briefSummary":490,"conditions":491,"keywords":517,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":110},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":488,"type":22},380,"10 Years","The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[492,32,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516],"Rare Diseases","Sarcoidosis","Phacomatosis","Pheochromocytoma","Paraganglioma","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Hypertrophic Cardiomyopathy","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","Cushing Syndrome","HHT","Hemorrhagic Hereditary Telangiectasia",[471,518,519,494,520,521,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,516],"amyloidosis","sarcoidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":524,"type":42},"2026-01-14",{"date":526,"type":42},"2024-07-01",{"date":528,"type":22},"2034-12-31",{"name":479,"class":109},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":110},"100438578","phase-2-minimal-residual-disease-response-adapted-deferral-of-transplant-in-dysproteinemia-milestone-100438578","NCT04991103","Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia - MILESTONE Trial","Inclusion Criteria:\n\n* Age \\>18 years with no upper age limit with a diagnosis of newly diagnosed multiple myeloma with indication for initiation of therapy with Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* No prior therapy except for dexamethasone (up to 160 mg) and\u002For bortezomib (up to 5.2 mg\u002Fm2 ) and\u002For cyclophosphamide up to 1000 mg\u002Fm2 administered for management of acute manifestations of multiple myeloma (hypercalcemia, renal impairment, pain) for no longer than 4 weeks prior to enrollment (pre induction). If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.\n* Measurable disease meeting at least one of the following criteria (at screening or prior to pre induction): 1) Serum monoclonal (M) protein ≥1.0 g\u002Fdl 2) ≥ 200 mg of M protein\u002F24h in the urine 3) Serum free light chain ≥10 mg\u002FdL and abnormal kappa to lambda ratio.\n* Life expectancy ≥ 12 months.\n* Adequate organ function - Hepatic function, with serum Alanine Aminotransferase ≤ 2.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg\u002FdL (34 µmol\u002FL) within 21 days prior to initiation of therapy. Creatinine clearance (CrCl) ≥ 40 mL\u002Fminute within 21 days prior to start of therapy.\n* Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception during treatment and for 30 days after the last dose of bortezomib. Male subjects must agree to practice contraception and refrain from donating sperm during treatment and for 90 days after the last dose of bortezomib.\n* All subjects must agree to comply with and be enrolled in Revlimid Risk Evaluation and Mitigation Strategy (REMS) program.\n* Meet institutional criteria for autologous hematopoietic cell transplantation according to investigator's assessment.\n* At least 30% ethnic\u002Fracial minorities will be included. If necessary, accrual will be held of non-ethnic minority patients while continuing for ethnic minorities in order to ensure at least 30% representation.\n\nExclusion Criteria:\n\n* Diagnosis of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes), Waldenstrom's macroglobulinemia.\n* Major surgery, radiotherapy or infection requiring therapy within 14 days of starting treatment.\n* Pregnant or lactating females.\n* Patients with uncontrolled human immunodeficiency virus, hepatitis B, hepatitis C. Patients may be eligible with Viral load is undetectable.\n* Unstable angina or myocardial infarction within 4 months prior to registration, New York heart association Class II, III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.\n* Cerebrovascular disease manifested as prior stroke at any time or transient ischemic attack in the 12 months prior to initiation of therapy.\n* Non hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or localized thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.\n* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 21 days prior to registration.\n* Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.",{"count":95,"type":22},[26],"This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma (cohort A) and amyloidosis (cohort B).",[197,32],[542,543],"Minimal residual disease","Autologous stem cell transplantation","2025-12-29",{"date":546,"type":42},"2025-12-31",{"date":548,"type":42},"2021-09-22",{"date":550,"type":22},"2028-08-27",{"name":552,"class":109},"University of Alabama at Birmingham",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":561,"conditions":562,"keywords":577,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":110},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":120,"type":22},"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[563,564,565,566,567,568,569,570,571,572,573,32,574,575,576],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Vasculitis","Peripheral Neuropathy","Thrombosis","RA Complications",[578,579,580,581],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":584,"type":42},"2025-12-24",{"date":586,"type":42},"2025-10-01",{"date":588,"type":22},"2026-06",{"name":590,"class":109},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":598,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":110},"100609583","a-study-of-myocardial-stiffness-in-amyloidosis-with-magnetic-resonance-elastography-100609583","NCT07216469","A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography","Myocardial Stiffness in Amyloidosis by Magnetic Resonance Elastography - AMREloid Study","Inclusion Criteria\n\nSubjects are eligible to be included in the study if all the following criteria apply:\n\n1. Adult, age 20 and greater\n2. Subject is clinically stable without cardiovascular-related hospitalizations within 2 weeks prior to enrollment as assessed by the investigators\n3. Subject is able to provide written informed consent and is willing and able to complete study procedures\n4. Subject must meet criteria for either ATTR cardiac amyloidosis or AL cardiac amyloidosis from review of medical records as specified below:\n\n   a. ATTR cardiac amyloidosis based on meeting all the following criteria:\n\n   i. Diagnosis of amyloidosis within ten years prior to study screening\n\n   ii. Transthyretin amyloid deposits in cardiac tissue OR Technetium (99mTc) bone scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness \\> 12 mm OR Transthyretin amyloid deposits in non-cardiac tissue with cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider\n\n   b. AL cardiac amyloidosis based on meeting all the following criteria:\n\n   i. Diagnosis of amyloidosis within ten years prior to study screening\n\n   ii. Histopathologic diagnosis of amyloidosis with AL protein identification\n\n   iii. Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness \\> 12 mm in the absence of other causes OR Elevated NT-proBNP (\\>332 ng\u002FL) in the absence of renal failure or atrial fibrillation OR Cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider\n\n   Exclusion Criteria\n\n   Patients are ineligible to be included in the study if any of the following criteria apply:\n\n1\\. Unable to consent or unable to complete all study procedures 2. Unable to ambulate for 6 minutes (confirmed at study coordinator visit) 3. Unable to maintain in supine position for 30 minutes 4. Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit) 5. Contraindications for safe MRI scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator) 6. Presence of implantable cardiac pacemaker or defibrillator 7. History of complex congenital heart disease, prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta 8. Significant artifact from prior MRI studies 9. Pregnant or breast-feeding women 10. Weight equal to or greater than 155 kg 11. In the judgment of the investigator, has clinically relevant ongoing medical condition or laboratory abnormalities or other condition that might jeopardize the participants safety, increase the participants risk from participation, interfere with the study, or confirmed study results","20 Years",{"count":600,"type":22},20,"This is a prospective case control study to determine the feasibility and utility of myocardial stiffness assessment by cardiac magnetic resonance elastography (MRE) in patients with cardiac amyloidosis.",[32],"2025-12-19",{"date":605,"type":42},"2025-12-26",{"date":607,"type":42},"2025-10-14",{"date":609,"type":22},"2027-11",{"name":214,"class":109},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":110},"100609755","a-study-of-mcg-in-cardiac-amyloidosis-100609755","NCT07218705","A Study Of MCG In Cardiac Amyloidosis","A Prospective Study of Magnetocardiography for Disease Detection and Monitoring Treatment Outcomes in Amyloidosis","Inclusion Criteria\n\n1. Age ≥ 18 years on the date of consent\n2. Ability for participant to comply with study requirements\n3. Written informed consent\n\nExclusion Criteria\n\n1. Pregnant or breastfeeding\n2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG\n3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).\n4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan\n5. Inability to lie down in a supine\u002Finclined position and stay still on the examination bed\n6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol",{"count":466,"type":22},"The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.",[32],"2025-12-15",{"date":582,"type":42},{"date":624,"type":42},"2025-12-03",{"date":609,"type":22},{"name":214,"class":109},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":18,"minAge":634,"maxAge":4,"enrollmentInfo":635,"targetDuration":637,"studyType":302,"phases":4,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":110},"100482046","cancer-and-aging-resilience-evaluation-in-older-adults-with-hematologic-malignancies-the-care-heme-registry-100482046","NCT05556928","Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry","CARE-Heme","Inclusion Criteria:\n\n* Patients are ≥50 years of age.\n* Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute\u002FChronic Myeloid Leukemia, Acute\u002FChronic Lymphoid Leukemia).\n* Patients have appointments at UAB including if they are an inpatient or other clinic locations.\n\nExclusion Criteria:\n\n* Individuals who are \\\u003C50 years old.\n* Patients who do not read and\u002For speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.","50 Years",{"count":636,"type":22},5000,"12 Months","The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.",[197,32,422],"2025-12-05",{"date":642,"type":42},"2025-12-08",{"date":644,"type":42},"2020-07-21",{"date":132,"type":22},{"name":552,"class":109},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":302,"phases":4,"briefSummary":657,"conditions":658,"keywords":659,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":110},"100556624","prevalence-of-amyloidosis-in-trauma-patients-100556624","NCT06527521","Prevalence of Amyloidosis in Trauma Patients","Prevalence of Amyloidosis in Trauma Patients Using Red Flags Tool","APTUR","Inclusion Criteria:\n\n* Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness \\> 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP \\> 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause.\n* Ability to cooperate in the necessary evaluations.\n* Signed informed consent for inclusion in the study, either by the participant or their legal representative.\n\nExclusion Criteria:\n\n\\- Participants previously diagnosed with amyloidosis cannot be included in the study.",{"count":656,"type":22},246,"This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.",[32],[32,660,661],"Red Flags tool","Traumatology","2025-12-01",{"date":664,"type":42},"2025-12-02",{"date":666,"type":42},"2024-11-13",{"date":668,"type":22},"2026-10",{"name":670,"class":109},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":672,"slug":673,"hasResults":12,"nctId":674,"briefTitle":675,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":677,"targetDuration":489,"studyType":302,"phases":4,"briefSummary":679,"conditions":680,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":687,"lastUpdatePostDateStruct":688,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":110},"100340846","registry-for-adults-with-plasma-cell-disorders-pcds-100340846","NCT03717844","Registry for Adults With Plasma Cell Disorders (PCD's)","Inclusion Criteria:\n\n* Patients have an outpatient appointment or are hospitalized inpatient at UNC Cancer Hospitals, or affiliated clinic settings or participating sites for the evaluation and management of a PCD.\n* Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and\u002For monoclonal plasma cell population. Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and\u002For heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy,Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia.\n* Age ≥18 years.\n* Must consent to participation in this study and agree to complete the assessment at baseline and follow-up time points.\n* Must be able to read and speak English.\n\nExclusion Criteria:\n\n* Physical or psychiatric\u002Fbehavioral illnesses or problems that the treating clinician feels would preclude successful participation in the study.\n* There are no imaging or lab studies required to determine eligibility.",{"count":678,"type":22},2000,"The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a \"geriatric assessment,\" as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).",[197,32,681,682,683,684,685,686,422],"Cryoglobulinemia","Castleman's Disease","Light Chain Deposition Disease","Heavy Chain Deposition Disease","Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes","Smoldering Multiple Myeloma","2025-11-19",{"date":689,"type":42},"2025-11-20",{"date":691,"type":42},"2018-02-09",{"date":693,"type":22},"2029-02",{"name":695,"class":109},"UNC Lineberger Comprehensive Cancer Center",{"id":697,"slug":698,"hasResults":12,"nctId":699,"briefTitle":700,"officialTitle":701,"acronym":4,"eligibilityCriteria":702,"healthyVolunteers":394,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":703,"targetDuration":704,"studyType":302,"phases":4,"briefSummary":705,"conditions":706,"keywords":708,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":719,"locationsCount":408},"100610813","18fft8-pet-imaging-in-immunoglobulin-light-chain-amyloidosis-100610813","NCT07232459","[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis","Clinical Study of [18F]FT8 PET\u002FCT in Evaluating Amyloidosis","1. Subject Recruitment Participants will be recruited from outpatients and\u002For inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.\n2. Amyloidosis Patients:\n\n2.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult patients (age ≥ 18 years);\n2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.\n3. Scheduled to undergo a clinical Pan-Amyloid PET\u002FCT scan as part of standard care or clinical evaluation.\n4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria\n\nSubjects will be excluded based on any of the following:\n\n1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.\n2. Pregnancy or breastfeeding.\n3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.\n\n3\\. Healthy Volunteers: 3.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult subjects (age ≥ 18 years);\n2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).\n3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:\n\nSubjects will be excluded based on any of the following:\n\n1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.\n2. Pregnancy or breastfeeding.\n3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.",{"count":7,"type":22},"7 Days","\\[18F\\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\\[18F\\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \\[18F\\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \\[18F\\]FT8 PET imaging in human subjects.",[74,347,32,707],"Healthy Subjects",[709,710,711],"PET\u002FCT","Cardiac amyloidosis","immunoglobulin light chain","2025-11-15",{"date":714,"type":42},"2025-11-18",{"date":716,"type":42},"2025-07-21",{"date":718,"type":22},"2028-12-20",{"name":720,"class":109},"Tianjin Medical University"]